AR026355A1 - Formulacion y metodo antidiabetico. - Google Patents
Formulacion y metodo antidiabetico.Info
- Publication number
- AR026355A1 AR026355A1 ARP000105804A ARP000105804A AR026355A1 AR 026355 A1 AR026355 A1 AR 026355A1 AR P000105804 A ARP000105804 A AR P000105804A AR P000105804 A ARP000105804 A AR P000105804A AR 026355 A1 AR026355 A1 AR 026355A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- treatment
- antidiabetic
- patients
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporciona una formulacion farmacéutica antidiabética de bajas dosis especialmente adaptada para el tratamiento de la diabetes de Tipo II en pacientessin experiencia en el fármaco, que incluye una combinacioan de metformina (empleada en una canti dad reducida (menos de 800 mg de metformina por día) comparacon al que se emplea en la práctica médica generalmente aceptada) y al menos algun otro agente antidiabético tal como una sulfonil urea, por ejemplo, gliburidacuya combinacion proporciona al menos alrededor de una eficacia sustancialmente equivalente en el tratamiento de la diabetes en pacientes sin experiencia en elfármaco, como las formulaciones antidiabéticas hechas que contienen metformina empleada en dosis prescritas en la práctica médica generalmente aceptada paraterapia de primera línea para el tratamiento de la diabetes, pero con efectos laterales sustancialemente reducidos, tales como hipoglicemia y/ogastrointestinal. Un método para el tratamiento de la diabetes en pacien tes sin exeriencia en el fármaco también se proporciona empleando la formulacionanterior para reducir la resistencia a la insulina y/o la excursion de glucosa post-prandial y/o la hemoglobina 1 Ac, y/o el incremento de la insulina post-prandial, por ello trantando la diabetes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/432,465 US6586438B2 (en) | 1999-11-03 | 1999-11-03 | Antidiabetic formulation and method |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026355A1 true AR026355A1 (es) | 2003-02-05 |
Family
ID=23716278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000105804A AR026355A1 (es) | 1999-11-03 | 2000-11-03 | Formulacion y metodo antidiabetico. |
Country Status (34)
Country | Link |
---|---|
US (2) | US6586438B2 (es) |
EP (1) | EP1253944A2 (es) |
JP (2) | JP2003529551A (es) |
KR (2) | KR20020050253A (es) |
CN (3) | CN101273981B (es) |
AR (1) | AR026355A1 (es) |
AU (1) | AU781781B2 (es) |
BG (2) | BG106732A (es) |
BR (1) | BR0015295A (es) |
CA (1) | CA2389931A1 (es) |
CZ (2) | CZ20021547A3 (es) |
DE (1) | DE60038455T2 (es) |
EE (1) | EE05210B1 (es) |
ES (1) | ES2302702T3 (es) |
GE (2) | GEP20053539B (es) |
HK (1) | HK1045655A1 (es) |
HU (1) | HUP0300642A3 (es) |
IL (3) | IL149138A0 (es) |
LT (1) | LT5025B (es) |
LV (1) | LV12907B (es) |
MX (1) | MXPA02004290A (es) |
MY (2) | MY136636A (es) |
NO (1) | NO20022086L (es) |
NZ (1) | NZ552074A (es) |
PL (1) | PL366112A1 (es) |
RO (1) | RO123109B1 (es) |
RU (1) | RU2276604C2 (es) |
SK (1) | SK4992002A3 (es) |
TN (2) | TNSN00206A1 (es) |
TW (1) | TWI241185B (es) |
UA (2) | UA76706C2 (es) |
UY (1) | UY26425A1 (es) |
WO (1) | WO2001032158A2 (es) |
ZA (2) | ZA200203367B (es) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235627B2 (en) * | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US20030040469A1 (en) * | 2000-03-08 | 2003-02-27 | Knudsen Liselotte Bjerre | Lowering serum lipids |
RU2281764C2 (ru) * | 2000-03-17 | 2006-08-20 | Адзиномото Ко., Инк. | Лекарственные средства для лечения осложнений, связанных с диабетом, и невропатии и их применения |
FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
US7062312B2 (en) * | 2001-01-17 | 2006-06-13 | Pediamed Pharmaceuticals, Inc. | Combination and method including a visual marker for determining compliance with a medication regimen |
US20030022816A1 (en) * | 2001-03-07 | 2003-01-30 | Knudsen Liselotte Bjerre | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
US20020187926A1 (en) * | 2001-03-07 | 2002-12-12 | Knudsen Liselotte Bjerre | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
CA2461693A1 (en) * | 2001-09-28 | 2003-04-03 | Sun Pharmaceutical Industries Limited | Dosage form for treatment of diabetes mellitus |
US6924311B2 (en) * | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
US7183321B2 (en) * | 2001-12-17 | 2007-02-27 | Bristol-Myers Squibb Company | Antidiabetic formulation and method |
US9045438B2 (en) | 2002-01-25 | 2015-06-02 | Silanes S.A. De C.V. | Pharmaceutical composition containing glimepiride and metformin hydrochloride |
EP1492511B3 (fr) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
EP1515701B1 (en) | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
ES2327328T3 (es) * | 2002-07-04 | 2009-10-28 | Zealand Pharma A/S | Glp-1 y procedimientos para el tratamiento de la diabetes. |
JP2004067575A (ja) * | 2002-08-06 | 2004-03-04 | Yaizu Suisankagaku Industry Co Ltd | 糖尿病治療薬効果促進剤 |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
SE526943C2 (sv) * | 2002-08-26 | 2005-11-22 | Indevex Ab | Födoämneskompositionsprodukt |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US20040147564A1 (en) * | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
ATE457166T1 (de) * | 2003-07-24 | 2010-02-15 | Wockhardt Ltd | Orale zusammensetzungen zur behandlung von diabetes |
WO2005012346A1 (en) * | 2003-07-25 | 2005-02-10 | Conjuchem, Inc. | Long lasting insulin derivatives and methods thereof |
US20050202063A1 (en) * | 2003-08-26 | 2005-09-15 | Ebn International Kft | Food product |
EP1732513A2 (en) * | 2003-12-31 | 2006-12-20 | Alpharma, Inc. | Rosiglitazone formulations |
EP1841414A1 (en) * | 2003-12-31 | 2007-10-10 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
EP1746993A4 (en) * | 2004-04-29 | 2007-08-29 | Andrx Labs Llc | METFORMIN COMPOSITIONS WITH CONTROLLED RELEASE |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
WO2006074278A2 (en) * | 2005-01-05 | 2006-07-13 | Mitsunori Ono | Compositions for treating diabetes or obesity |
KR20070102694A (ko) * | 2005-01-31 | 2007-10-19 | 아지노모토 가부시키가이샤 | 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물 |
EP1889618A4 (en) * | 2005-05-27 | 2010-11-24 | Daiichi Sankyo Co Ltd | COMBINED MEDICINE FOR THE TREATMENT OF DIABETES |
AU2006326658A1 (en) * | 2005-12-09 | 2007-06-21 | Metaproteomics, Llc | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
GEP20105033B (en) * | 2005-12-28 | 2010-06-25 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CA2873524C (en) | 2006-05-04 | 2018-02-20 | Boehringer Ingelheim International Gmbh | A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
WO2008011713A1 (en) * | 2006-07-26 | 2008-01-31 | Diamedica Inc. | Methods of diagnosis and treatment for metabolic disorders |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
US20100136561A1 (en) * | 2008-05-16 | 2010-06-03 | Interleukin Genetics, Inc. | Genetic Markers for Weight Management and Methods of Use Thereof |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101189639B1 (ko) * | 2008-12-15 | 2012-10-12 | 씨제이제일제당 (주) | 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법 |
ES2811342T3 (es) | 2009-03-31 | 2021-03-11 | Ligand Pharm Inc | Antagonista de receptores de endotelina y angiotensina II de bifenilsulfonamida para tratar glomeruloesclerosis y nefropatía inducida por IgA |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
CN101810628B (zh) * | 2010-04-13 | 2012-05-23 | 北京四环科宝制药有限公司 | 二甲双胍格列吡嗪片及其制备方法 |
NZ603169A (en) | 2010-04-27 | 2015-02-27 | Zealand Pharma As | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
JP6227406B2 (ja) | 2010-05-11 | 2017-11-08 | ヤンセン ファーマシューティカ エヌ.ベー. | SGLTの阻害剤としての1−(β−D−グルコピラノシル)−2−チエニル−メチルベンゼン誘導体を含有する医薬製剤 |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
WO2012090225A2 (en) * | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
MX2013007884A (es) | 2011-01-07 | 2013-09-13 | Elcelyx Therapeutics Inc | Terapias a base de ligando del receptor quimiosensorial. |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
CN104144704B (zh) | 2011-11-03 | 2018-03-23 | 西兰制药公司 | Glp‑1受体激动剂肽胃泌素缀合物 |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2012363873B2 (en) | 2012-01-06 | 2017-11-23 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
CN110693867A (zh) | 2012-01-06 | 2020-01-17 | 埃尔舍利克斯治疗公司 | 用于治疗代谢性病症的组合物和方法 |
WO2013115742A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Pharmaceutical composition comprising alpha-glucosidase inhibitor |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
LT2854841T (lt) | 2012-06-04 | 2017-06-12 | Diamedica Inc. | Kalikreino 1 iš žmogaus audinio glikozilinimo izoformos |
MX356957B (es) | 2012-07-23 | 2018-06-20 | Zealand Pharma As | Analogos del glucagon. |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
KR101336499B1 (ko) * | 2013-03-06 | 2013-12-03 | 씨제이제일제당 (주) | 당뇨병의 예방 또는 치료용 복합 조성물 |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
SG11201602965WA (en) | 2013-10-17 | 2016-05-30 | Zealand Pharma As | Acylated glucagon analogues |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
CN107636010B (zh) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | 酰化胰高血糖素类似物 |
JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
CN117384274A (zh) | 2016-12-09 | 2024-01-12 | 西兰制药公司 | 酰化的glp-1/glp-2双重激动剂 |
EP3592377A4 (en) | 2017-03-09 | 2021-02-17 | Diamedica Inc. | DOSAGE FORMS OF TISSUE KALLIKREIN 1 |
JP2022502373A (ja) * | 2018-09-24 | 2022-01-11 | ペンデュラム セラピューティクス, インコーポレイテッド | 微生物組成物および使用方法 |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
CN113648318B (zh) * | 2020-05-12 | 2023-08-25 | 中国科学院上海营养与健康研究所 | 增强细胞产热和治疗疾病的应用 |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US4060634A (en) | 1973-09-26 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Rapidly resorbable glibenclamide |
DE2348334C2 (de) | 1973-09-26 | 1982-11-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
EP0062704A1 (de) | 1980-12-03 | 1982-10-20 | Hoechst Aktiengesellschaft | Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US4916163A (en) | 1985-06-04 | 1990-04-10 | The Upjohn Company | Spray-dried lactose formulation of micronized glyburide |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
DE3833439A1 (de) | 1988-10-01 | 1991-09-12 | Hoechst Ag | Verfahren zur mikronisierung von glibenclamid |
US5258185A (en) * | 1989-08-23 | 1993-11-02 | Bauer Kurt H | Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
DE4323636A1 (de) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
AU729529B2 (en) * | 1997-06-06 | 2001-02-01 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
ATE201139T1 (de) | 1997-06-13 | 2001-06-15 | Novo Nordisk As | Neue dosierung für diabetes type 2 |
CZ298469B6 (cs) | 1997-06-18 | 2007-10-10 | Smithkline Beecham Plc | Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus |
GB9715306D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
KR20010024533A (ko) | 1997-10-17 | 2001-03-26 | 오흘러 로스 제이. | 퀴놀린 유도체의 치료적 용도 |
CA2312990C (en) | 1997-12-08 | 2008-04-29 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
FR2774591B1 (fr) | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
FI111167B (fi) * | 1998-02-24 | 2003-06-13 | Kemira Chemicals Oy | Menetelmä lietteen säilyvyyden parantamiseksi |
AU2610599A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
ATE250418T1 (de) | 1998-07-15 | 2003-10-15 | Merck Sante Sas | Tabletten enthaltend eine kombination von glibenclamid und metformin |
JP2002524517A (ja) | 1998-09-17 | 2002-08-06 | ブリストル−マイヤーズ スクイブ カンパニー | aP2阻害剤およびその組成物を用いる糖尿病の治療方法 |
CO5200844A1 (es) | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
EP2620443A1 (en) | 2012-01-25 | 2013-07-31 | Galecto Biotech AB | Novel galactoside inhibitors of galectins |
-
1999
- 1999-11-03 US US09/432,465 patent/US6586438B2/en not_active Expired - Lifetime
- 1999-12-14 US US09/460,920 patent/US7598262B2/en not_active Expired - Lifetime
-
2000
- 2000-10-13 JP JP2001534363A patent/JP2003529551A/ja active Pending
- 2000-10-13 BR BR0015295-1A patent/BR0015295A/pt not_active Application Discontinuation
- 2000-10-13 CN CN2008100817553A patent/CN101273981B/zh not_active Expired - Lifetime
- 2000-10-13 SK SK499-2002A patent/SK4992002A3/sk not_active Application Discontinuation
- 2000-10-13 EE EEP200200241A patent/EE05210B1/xx not_active IP Right Cessation
- 2000-10-13 CN CNB008180288A patent/CN100386114C/zh not_active Expired - Lifetime
- 2000-10-13 UA UA2002054480A patent/UA76706C2/uk unknown
- 2000-10-13 CN CN2011101796999A patent/CN102283853A/zh active Pending
- 2000-10-13 ES ES00972122T patent/ES2302702T3/es not_active Expired - Lifetime
- 2000-10-13 DE DE60038455T patent/DE60038455T2/de not_active Expired - Lifetime
- 2000-10-13 GE GE4802A patent/GEP20053539B/en unknown
- 2000-10-13 HU HU0300642A patent/HUP0300642A3/hu unknown
- 2000-10-13 RU RU2002113764/15A patent/RU2276604C2/ru not_active IP Right Cessation
- 2000-10-13 UA UA2002054481A patent/UA75583C2/uk unknown
- 2000-10-13 KR KR1020027005677A patent/KR20020050253A/ko not_active Application Discontinuation
- 2000-10-13 NZ NZ552074A patent/NZ552074A/en not_active IP Right Cessation
- 2000-10-13 CZ CZ20021547A patent/CZ20021547A3/cs unknown
- 2000-10-13 EP EP00970913A patent/EP1253944A2/en not_active Withdrawn
- 2000-10-13 GE GE4798A patent/GEP20053538B/en unknown
- 2000-10-13 AU AU80229/00A patent/AU781781B2/en not_active Ceased
- 2000-10-13 WO PCT/US2000/028467 patent/WO2001032158A2/en active IP Right Grant
- 2000-10-13 MX MXPA02004290A patent/MXPA02004290A/es not_active Application Discontinuation
- 2000-10-13 KR KR1020027005673A patent/KR100769786B1/ko active IP Right Grant
- 2000-10-13 CA CA002389931A patent/CA2389931A1/en not_active Abandoned
- 2000-10-13 IL IL14913800A patent/IL149138A0/xx active IP Right Grant
- 2000-10-13 RO ROA200200560A patent/RO123109B1/ro unknown
- 2000-10-13 PL PL00366112A patent/PL366112A1/xx not_active Application Discontinuation
- 2000-10-13 CZ CZ20021546A patent/CZ304090B6/cs not_active IP Right Cessation
- 2000-10-24 MY MYPI20004995A patent/MY136636A/en unknown
- 2000-10-24 MY MYPI20004996A patent/MY125118A/en unknown
- 2000-10-27 TW TW089122629A patent/TWI241185B/zh not_active IP Right Cessation
- 2000-10-27 TN TNTNSN00206A patent/TNSN00206A1/en unknown
- 2000-10-27 TN TNTNSN00207A patent/TNSN00207A1/en unknown
- 2000-11-02 UY UY26425A patent/UY26425A1/es unknown
- 2000-11-03 AR ARP000105804A patent/AR026355A1/es unknown
-
2002
- 2002-04-15 IL IL149139A patent/IL149139A/en active IP Right Grant
- 2002-04-15 IL IL149138A patent/IL149138A/en not_active IP Right Cessation
- 2002-04-26 ZA ZA200203367A patent/ZA200203367B/xx unknown
- 2002-04-26 ZA ZA200203368A patent/ZA200203368B/xx unknown
- 2002-05-02 NO NO20022086A patent/NO20022086L/no unknown
- 2002-05-22 BG BG106732A patent/BG106732A/bg unknown
- 2002-05-22 BG BG106733A patent/BG65850B1/bg unknown
- 2002-05-24 LT LT2002062A patent/LT5025B/lt not_active IP Right Cessation
- 2002-06-03 LV LVP-02-93A patent/LV12907B/en unknown
- 2002-09-30 HK HK02107208.1A patent/HK1045655A1/zh unknown
-
2012
- 2012-09-25 JP JP2012211400A patent/JP2013028631A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR026355A1 (es) | Formulacion y metodo antidiabetico. | |
BR0109336A (pt) | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico | |
EP1379232B1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
JP2018138578A5 (es) | ||
US7575757B2 (en) | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof | |
BR112013005907B1 (pt) | Composição farmacêutica parenteral | |
AR026356A1 (es) | Metodo para tratar la diabetes | |
AR047779A1 (es) | Composiciones y metodos para tratar diabetes | |
EP2635269B1 (en) | A combination composition | |
McKinney et al. | Reversal of severe tricyclic antidepressant-induced cardiotoxicity with intravenous hypertonic saline solution | |
US20060257388A1 (en) | Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof | |
KR880005933A (ko) | 비타민 b6-함유 약제학적 제제 | |
MXPA04007183A (es) | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. | |
RU2543635C2 (ru) | Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости | |
JP2002510645A5 (es) | ||
CA2489526C (en) | Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof | |
Kadhe et al. | Advances in drug delivery of oral hypoglycemic agents | |
CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
Saravu et al. | Near-fatal amlodipine poisoning. | |
Joshi et al. | Designer insulins regimens in clinical practice-pilot multicenter Indian study | |
JP2001316293A5 (es) | ||
Trifu et al. | Modern aspects regardind the use of local anesthetic medicines in dermatologic surgery | |
RU2023129893A (ru) | Фармацевтическая композиция для профилактики или лечения сахарного диабета у животного семейства псовые, содержащая энавоглифлозин | |
JP2009526819A (ja) | 塩酸プリロカインを有する新規の高比重組成物、この新規の組成物の髄腔内麻酔への使用、及びこの組成物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |